Retraction for Wang and Gao

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epithelial ovarian cancer (EOC) often develops resistance to poly ADP-ribose polymerase inhibitors (PARPi).
• Understanding the mechanisms of PARPi resistance is crucial for developing effective treatment strategies.
• Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are emerging as potential agents in cancer therapy.

Purpose of the Study:

• To investigate the mechanisms of PARPi resistance in EOC.
• To evaluate the efficacy of combining PARPi with CDK4/6i in overcoming this resistance.
• To identify potential biomarkers for predicting treatment response.

Main Methods:

• Development of drug-resistant EOC cell lines (A2780-ola-r, SKOV-3-ola-r) through PARPi treatment.
• Treatment of resistant cell lines with Olaparib (PARPi), Palbociclib (CDK4/6i), and their combination at low doses.
• Bioinformatics analysis to identify potential therapeutic targets.
• Cell cycle analysis, immunofluorescence, and Western blot to assess treatment effects on DNA repair pathways and protein expression.

Main Results:

• Low-dose combination therapy significantly reduced tumor cell proliferation in resistant EOC cell lines.
• Combination treatment induced G1 phase cell cycle arrest and altered DNA damage markers (reduced RAD51, increased p-γH2AX).
• Bioinformatics identified KNSTRN and TRPC4AP as potential targets, with TRPC4AP levels positively correlating with treatment response.

Conclusions:

• Combining PARPi with CDK4/6i is a viable strategy to overcome PARPi resistance in EOC.
• KNSTRN and TRPC4AP may serve as predictive biomarkers for the efficacy of this combination therapy.
• This approach holds promise for improving treatment outcomes in patients with EOC resistant to PARPi.